Gilead Sciences Expands Liver Portfolio With Acquisition Of CymaBay Therapeutics
February 12, 2024
-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 --
-- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC --
-- Acquisition Expands Gilead’s Long-Standing Commitment to Patients with Liver Diseases --
https://investors.gilead.com/news/n...uisition-of-CymaBay-Therapeutics/default.aspx
Gilead Sciences Expands Liver Portfolio With Acquisition Of...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.31 |
Change
-0.790(3.93%) |
Mkt cap ! $2.465B | |||
| Open | High | Low | Value | Volume |
| $19.86 | $19.99 | $17.97 | $22.67M | 1.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2222 | $19.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.31 | 8162 | 3 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.25 |
Change
-0.790 ( 4.18 %) |
||||
| Open | High | Low | Volume | ||
| $19.88 | $19.88 | $17.97 | 249066 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| NEU (ASX) Chart |